INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Phase 3RecruitingNCT06295731

Inhibrx Biosciences, Inc410 enrolled

Overview

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

410

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

INBRX-106DRUG

INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)

PembrolizumabDRUG

Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Has histologically or cytologically confirmed diagnosis of metastatic, recurrent head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies. * Has tumor PD-L1 expression of CPS ≥20. Tumor tissue must be provided for PD-L1 biomarker analysis. * Has human papilloma virus (HPV) testing results for oropharyngeal cancer by p16 immunohistochemistry (IHC) testing. * Has measurable disease per RECIST 1.1 guidelines. * Has the primary tumor location of the oral cavity, oropharynx, hypopharynx, or larynx. * Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Female patients of childbearing potential must have a negative highly sensitive pregnancy test within 72 hours prior to randomization and must not be breastfeeding. * Male and female patients of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use a highly effective method of contraception. Exclusion Criteria: * Has primary tumor site (any histology) of nasopharynx or salivary glands or occult primary site. * Has received prior systemic therapy (eg, prior chemo-, immune-, or biologic therapy) for locally advanced unresectable or metastatic HNSCC. * Prior systemic therapy completed \>6 months prior to signing informed consent is allowed if given as part of multimodal treatment for locoregionally advanced disease with curative intent, and no PD/recurrence occurred within 6 months of its completion. Prior systemic immunotherapy in the locoregionally advanced disease with curative intent, including but not limited to anti-PD-(L)1 agents, is allowed if PD/recurrence occurred ≥12 months after its completion. * Has clinically active central nervous system metastases and/or carcinomatous meningitis. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. * Rapidly progressing disease or with features that may confer a high risk of tumor-associated hemorrhage or uncontrolled tumor pain. * Current or history of immune-related disease that required systemic treatment in past 2 years, except for replacement therapy.

Locations (88)

Outcomes

Primary Outcomes

Phase 2: Objective Response Rate (ORR)

ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Time frame: up to 6 months

Phase 3: Progression-Free Survival (PFS)

PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first).

Time frame: From randomization to first occurrence of progressive disease (PD) or death (up to 4 years)

Phase 3: Overall Survival (OS)

OS is the time from randomization to death due to any cause

Time frame: From randomization until death from any cause (up to 4 years)

Secondary Outcomes

Phase 3: Objective Response Rate (ORR)

ORR is defined as the proportion of patients with a CR or PR on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Time frame: From randomization until treatment discontinuation (up to 2 years)

Duration of Response (DOR)

DOR is defined as the time from the first occurrence of a documented objective response to PD, as determined by the Investigator according to RECIST v1.1, or death from any cause (whichever occurs first)

Time frame: From the first occurrence of a documented objective response to PD or death (up to 4 years)

Clinical Benefit Rate (CBR)

CBR is defined as the proportion of patients with stable disease (SD) for ≥12 weeks or a CR or PR, as determined by the Investigator according to RECIST v1.1.

Central Contacts

Study Director - Inhibrx

CONTACT

858-500-7833 clinicaltrials@inhibrx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

City of Hope Medical Center

Duarte, California, United States

RECRUITING

Los Angeles Cancer Network (LACN)

Los Angeles, California, United States

RECRUITING

Sutter Health

Sacramento, California, United States

RECRUITING

UC Davis

Sacramento, California, United States

RECRUITING

Medical Oncology Associates of San Diego

San Diego, California, United States

RECRUITING

Sarcoma Oncology Center

Santa Monica, California, United States

RECRUITING

ChristianaCare Health Services

Newark, Delaware, United States

RECRUITING

University of Florida UF Health Cancer Center

Gainesville, Florida, United States

RECRUITING

The Oncology Institute of Hope & Innovation

Miami, Florida, United States

RECRUITING

Mid Florida Hematology and Oncology Center

Orange City, Florida, United States

RECRUITING

...and 78 more locations